|
2024
|
Invention
|
Polymorphic compounds and uses thereof. The present invention provides co-crystal and salt forms,... |
|
|
Invention
|
Stable salt and crystal forms of 2-[3-({1-[2-(dimethylamino)ethyl]-2-(2,2-dimethylpropyl)-1h-1,3-... |
|
2023
|
Invention
|
Ep4 inhibitors and synthesis thereof.
The present invention provides N-((4-(2-ethyl-4,6-dimethyl... |
|
|
Invention
|
Ep4 inhibitors and use thereof.
The present invention provides use of an agent that inhibits EP4... |
|
2021
|
Invention
|
Use of ep4 receptor antagonists for the treatment of liver cancer, melanoma, lymphoma and leukemi... |
|
|
Invention
|
Selective ep4 receptor antagonistic substance for treatment of cancer. This invention provides a ... |
|
2020
|
Invention
|
Process for the differential solubility-driven asymmetric transformation of substituted 2h-chrome... |
|
2019
|
Invention
|
Grapiprant unit dosage forms.
The present invention provides grapiprant unit dosage forms, and m... |
|
|
Invention
|
Grapiprant unit dosage forms. The present invention provides grapiprant unit dosage forms, and me... |
|
|
Invention
|
Ep4 inhibitors and synthesis thereof. The present invention provides N-((4-(2-ethyl-4,6-dimethyl-... |
|
|
Invention
|
Use of ep4 receptor antagonists for the treatment of nash-associated liver cancer. This invention... |
|
|
Invention
|
Ep4 inhibitors and use thereof. The present invention provides use of an agent that inhibits EP4 ... |
|
2018
|
Invention
|
Use of ep4 receptor antagonists in the treatment of cartilage disease. The invention is a method ... |
|
2017
|
Invention
|
Use of ep4 receptor antagonists for the treatment of nash-associated liver cancer. This inv... |
|
|
Invention
|
Use of ep4 receptor antagonists in the treatment of cartilage disease. This invention relates to ... |
|
2014
|
Invention
|
Therapeutic agent for ocular disease. The purpose of this invention is to provide a compound for ... |
|
|
Invention
|
Therapeutic agent for ocular disease. The problem addressed by the present invention is to provid... |
|
|
Invention
|
Therapeutic agent for eye disorder. The problem addressed by the present invention is to provide ... |
|
|
Invention
|
Use of ep4 receptor antagonists in the treatment of cartilage disease.
This invention relates to... |
|
|
Invention
|
Salts and crystal forms. This invention relates to salts and crystal forms of (S)-6-chloro-7-(1,1... |
|
2012
|
Invention
|
Pharmaceutical composition. The present invention provides a pharmaceutical composition which pre... |
|
|
Invention
|
Pharmaceutical composition. The present invention provides a pharmaceutical composition whi... |
|
2011
|
Invention
|
Use of ep4 receptor antagonists in the treatment of il-23 mediated diseases. This invention relat... |
|
|
Invention
|
5-ht4 receptor agonists for the treatment of dementia. This invention relates to a compound of fo... |
|
2010
|
Invention
|
Selective ep4 antagonistic substance for treatment of cancer. This invention provides a me... |
|
|
Invention
|
N-substituted saturated heterocyclic sulfone compounds with cb2 receptor agonistic activity. 7, k... |
